The Albumin–Bilirubin Score Is a Prognostic Factor for Gastric Cancer Patients Who Receive Curative Treatment

Background/Aim: The albumin-bilirubin (ALBI) score is a promising tool for the evaluation of the perioperative hepatic function. The present study aimed to evaluate the clinical impact of the preoperative ALBI status in patients with gastric cancer (GC) who received curative treatment. Patients and...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2022-08, Vol.42 (8), p.3929-3935
Main Authors: Ju, Miwha, Aoyama, Toru, Komori, Keisuke, Tamagawa, Hiroshi, Tamagawa, Ayako, Maezawa, Yukio, Morita, Junya, Onodera, Atsushi, Endo, Kazuya, Hashimoto, Itaru, Kano, Kazuki, Hara, Kentaro, Cho, Haruhiko, Nakazono, Masato, Segami, Kenki, Ishiguro, Tetsushi, Onuma, Shizune, Oshima, Takashi, Yukawa, Norio, Rino, Yasushi
Format: Article
Language:English
Subjects:
Albumin
Albumins
Bilirubin
Cancer
Chemotherapy
Gastric cancer
Multivariate analysis
Patients
Risk analysis
Risk factors
Statistical analysis
Survival
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background/Aim: The albumin-bilirubin (ALBI) score is a promising tool for the evaluation of the perioperative hepatic function. The present study aimed to evaluate the clinical impact of the preoperative ALBI status in patients with gastric cancer (GC) who received curative treatment. Patients and Methods: The present study included 244 patients who underwent curative treatment for GC between 2005 and 2018. The risk factors for overall survival (OS) and recurrence-free survival (RFS) were identified. Results: Based on the 3- and 5-year OS rates, we set the cut-off value for the ALBI score at -2.7849. The 3- and 5-year OS rates were 87.3% and 80.9%, respectively, in the ALBI-low group, and 66.9% and 60.6% in the ALBI-high group; these differences were statistically significant (p
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.15887